The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)

Br J Cancer. 2004 May 17;90(10):2025-31. doi: 10.1038/sj.bjc.6601824.

Abstract

In this report we show that mithramycin considerably increases the direct cytotoxic effect of tumour necrosis factor (TNF) on tumour cells in vitro. Sensitisation to TNF-induced apoptosis was prevented by the broad caspase inhibitor zVAD-fmk, whereas overexpression of Bcl-2 had no effect. Mithramycin also potentiated cell death induced by Fas agonistic antibodies. In contrast, mithramycin reduced the percentage of cells undergoing apoptosis due to factor withdrawal. TNF-induced activation of NF-kappaB (NF-kappaB)-dependent gene expression was not modulated by mithramycin treatment. Concomitantly with the increased sensitivity, the protein level of the short-spliced cFLIP variant was downregulated. These results indicate that mithramycin enhances TNF-induced cell death in an NF-kappaB-independent manner, and suggest that the Fas-associated death domain protein plays a crucial role in the TNF-sensitising effect of mithramycin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing*
  • Apoptosis / drug effects*
  • Carrier Proteins / pharmacology*
  • Drug Resistance, Neoplasm
  • Fas-Associated Death Domain Protein
  • Gene Expression Regulation, Neoplastic / drug effects
  • Humans
  • Leukemia, Erythroblastic, Acute / pathology
  • Leukemia, Promyelocytic, Acute / pathology
  • Plicamycin / analogs & derivatives*
  • Plicamycin / pharmacology*
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha / pharmacology*
  • fas Receptor

Substances

  • Adaptor Proteins, Signal Transducing
  • Carrier Proteins
  • FADD protein, human
  • Fas-Associated Death Domain Protein
  • Tumor Necrosis Factor-alpha
  • fas Receptor
  • mithramycin A
  • Plicamycin